COLORADO BLOOD CANCER INSTITUTE

Verismo Therapeutics dosed the first patient in the CELESTIAL-301 Phase 1 trial for SynKIR™-310, targeting relapsed/refractory B cell Non-Hodgkin Lymphomas. The trial aims to evaluate safety, tolerability, and efficacy, focusing on prolonged T cell function to prevent relapse. SynKIR™-310 uses a unique KIR-CAR platform for improved anti-tumor persistence.

Verismo Therapeutics dosed the first patient in the CELESTIAL-301 Phase 1 trial for SynKIR™-310, targeting relapsed/refractory B cell Non-Hodgkin Lymphomas. The trial evaluates safety, tolerability, and efficacy, aiming to improve T cell persistence and prevent relapse in advanced B cell lymphomas.

Verismo Therapeutics dosed the first patient in the CELESTIAL-301 Phase 1 trial for SynKIR™-310, targeting relapsed/refractory B cell Non-Hodgkin Lymphomas. This trial evaluates safety, tolerability, and efficacy, aiming to improve T cell persistence and combat relapse, offering new hope for patients with limited treatment options.

Verismo Therapeutics secures up to $4.05M from IFLI to accelerate SynKIR-310's clinical development for B-cell non-Hodgkin lymphoma. The phase 1 trial aims to enroll 18 patients by December 2028, focusing on safety and efficacy. Verismo, now a subsidiary of HLB Group, leverages its KIR-CAR platform for cancer treatments.

Verismo Therapeutics activated the CELESTIAL-301 Phase 1 trial at Sarah Cannon Research Institute to evaluate SynKIR™-310's safety and efficacy in treating relapsed/refractory B-cell NHL. The trial targets patients post-CAR T therapy relapse or those untreated, aiming to improve T cell persistence and prevent relapse, addressing a significant unmet medical need.

Verismo Therapeutics, a clinical-stage CAR-T company, has initiated its CELESTIAL-301 Phase 1 clinical trial at the Colorado Blood Cancer Institute to evaluate SynKIR™-310, a novel treatment for relapsed/refractory B-cell Non-Hodgkin Lymphomas. The trial aims to assess safety, tolerability, and preliminary efficacy in patients with B-cell NHL, including DLBCL, FL, MCL, and MZL. SynKIR™-310 leverages Verismo's KIR-CAR platform and proprietary CD19 binder, potentially improving T cell persistence and preventing early disease relapse. The trial addresses high unmet medical needs, as current CAR T cell therapies result in relapse in 40-50% of patients. Verismo received FDA clearance in May 2024 to proceed with this multicenter trial.